Table 1 Clinical and laboratory characteristics of adult cohort
AOSD | Control group | |
|---|---|---|
Number | 30 | 65 |
Mean Age (SD; Range) | 39 (±16.9; 19–72) | 50.9 (±13.5; 23–81) |
Sex (male:female) | 4:1 | 1.5:1 |
Swollen joints per patient* n (Range) | 0 (0–16) | 0 (0–23) |
Patients with swollen joints n (%) | 12 (40) | 17 (26) |
Tender joints per patient* n (Range) | 1 (0–24) | 0 (0–36) |
Patients with tender joints n (%) | 17 (57) | 31 (48) |
Arthralgia n (%) | 21 (70) | 40 (62) |
Erosive arthritis n | 3 | 3 |
Fever n (%) | 20 (66) | 31 (48) |
Rash n (%) | 13 (43) | 4 (6,2) |
Pharyngitis/sore throat n (%) | 8 (27) | 4 (6,2) |
Splenomegaly n (%) | 6 (20) | 3 (4,6) |
Lymphadenopathy n (%) | 2 (6.7) | 1 (1,5) |
Serositis (Pleuritis/Pericarditis/Peritonitis) n (%) | 3 (10) | 4 (6,2) |
Prednisolone Therapy at IL-18 determination n (%) | 15 (50) | 24 (37) |
DMARD Therapy | 11 (37) | 16 (25) |
WBC > 10,000/ml n (%) | 11 (37) | 22 (34) |
WBC Gpt/ml (SD; Range) | 11.7 (± 8.6; 3.9–46.5) | 9.4 (± 4.1; 2.3–21.5) |
Neutrophils > 80% n (%) | 11 (37) | 13 (20) |
ANA > 1:160 n (%) | 3 (10) | 6 (0.09) |
Elevated ALAT or ASAT n (%) | 9 (30) | 17 (26) |
ALAT μmol/ls (SD) | 0.83 (±0.96; 0.23–4.99) | 0.73 (±0.63; 0.1–4.8) |
RF positive n (%) | 1 (0.03) | 13 (20) |
CRP mg/l (SD; Range) | 76.3 (±71.5; < 5–231.7) | 45.5 (±62.3; < 5–220) |
ESR mm/1 h (SD; Range) | 45.0 (±30.1; 1–95) | 46.7 (±37.5; 2–150) |
RBC Tpt/l (SD; Range) | 4.29 (±0.57; 3.18–5.29) | 4.37 (±0.95; 2.25–9.6) |
Hemoglobin mmol/l (SD; Range) | 7.7 (±1.1; 5.6–10) | 7.8 (±1.2; 4.3–10) |
Hematocrit % (SD; Range) | 0.37 (±0.05;0.27–0.46) | 0.38 (±0.05;0.21–0.48) |
Platelets Gpt/l (SD; Range) | 310 (±115.3; 126–624) | 326 (±115.4; 83–621) |
IL-18 pg/ml* (Range) | 10,425 (100–408,000) | 355 (87.2–6600) |